JPRN-UMIN000002604已完成4 期
Combined therapy of infliximab with surgery in maintenance of remission in Crohn's disease - Combined therapy of infliximab with surgery in Crohn's disease
Clinical Research Group of inflammatory bowel disease in Japan0 个研究点目标入组 100 人开始时间: 2009年11月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria include 1) 3 or more surgeries in the past, 2) presence of the stoma, 3) multiple anastomosis, 4) 4 or more strictureplasties, or 5) other types of strictureplasty excepting Heineke-Mickulicz type. A patient is also excluded when doctors in charge of the patient consider that exclusion of the patient is preferable.
研究者
相似试验
已完成
Unknown
Study of Infliximab Therapy for Multiple Treatment(included IVIG)-resistant Kawasaki DiseaseKawasaki DiseaseJPRN-jRCT1091220201Investigator-initiated Clinical Research(in-house)20
招募中
不适用
Retreatment with subcutaneous Infliximab in patients with refractory Crohn’s diseaseK50Crohn disease [regional enteritis]DRKS00030670niversitätsklinikum Freiburg30
尚未招募
不适用
Induction of the remission by use of infliximab in RARheumatoid arthritisJPRN-UMIN000003344Division of Rheumatology, Department of Internal Medicine, Kanazawa University Hospital20
进行中（未招募）
不适用
Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial - INFASTModerate-to-severe active axial spondyloarthritisMedDRA version: 9.1Level: LLTClassification code 10058338Term: SpondylarthritisEUCTR2008-000982-51-DKSchering-Plough Research Institute, a Division of Schering Corporation150
进行中（未招募）
1 期
Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial - INFASTModerate-to-severe active axial spondyloarthritisMedDRA version: 9.1Level: LLTClassification code 10058338Term: SpondylarthritisEUCTR2008-000982-51-BESchering-Plough Research Institute, a Division of Schering Corporation150